RT Journal Article
SR Electronic
T1 Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD protein vaccine against COVID-19 in adults: pooled analysis of two randomized, double-blind, placebo-controlled, phase 1 and 2 trials
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.20.20248602
DO 10.1101/2020.12.20.20248602
A1 Yang, Shilong
A1 Li, Yan
A1 Dai, Lianpan
A1 Wang, Jianfeng
A1 He, Peng
A1 Li, Changgui
A1 Fang, Xin
A1 Wang, Chenfei
A1 Zhao, Xiang
A1 Huang, Enqi
A1 Wu, Changwei
A1 Zhong, Zaixin
A1 Wang, Fengze
A1 Duan, Xiaomin
A1 Tian, Siyu
A1 Wu, Lili
A1 Liu, Yan
A1 Luo, Yi
A1 Chen, Zhihai
A1 Li, Fangjun
A1 Li, Junhua
A1 Yu, Xian
A1 Ren, Hong
A1 Liu, Lihong
A1 Meng, Shufang
A1 Yan, Jinghua
A1 Hu, Zhongyu
A1 Gao, Lidong
A1 Gao, George F.
YR 2020
UL http://medrxiv.org/content/early/2020/12/22/2020.12.20.20248602.abstract
AB Background A safe and effective coronavirus disease 2019 (COVID-19) vaccine is urgently needed to control the ongoing pandemic. Although progress has been made recently with several candidates reporting positive efficacy results, COVID-19 vaccines developed so far cannot meet the global vaccine demand. We developed a protein subunit vaccine against COVID-19, using dimeric form of receptor-binding domain (RBD) as the antigen. We aimed to assess the safety and immunogenicity of this vaccine in humans and determine the appropriate dose and schedule for an efficacy study.Methods We did two randomized, double-blind, placebo-controlled, phase 1 and 2 trials for an RBD-based protein subunit vaccine, ZF2001. In phase 1 study, 50 healthy adults aged 18-59 years were enrolled and randomly allocated to three groups to receive three doses of vaccine (25 μg or 50 μg RBD-dimer, with adjuvant) or placebo (adjuvant-only) intramuscularly, 30 days apart. In phase 2 study, 900 healthy adults aged 18-59 years were enrolled and randomly allocated to six groups to receive vaccine (25 μg or 50 μg RBD-dimer, with adjuvant) or placebo (adjuvant-only) intramuscularly, with the former 3 groups given two doses and the latter 3 groups given three doses, 30 days apart. For phase 1 trial, the primary outcome was safety, as measured by the occurrence of adverse events and serious adverse events. The secondary outcome was immunogenicity as measured by the seroconversion rate and magnitude of antigen-binding antibodies, neutralizing antibodies and T-cell cytokine production. For phase 2 trial, the primary outcome included both safety and immunogenicity. These trials are registered with ClinicaTrials.gov, NCT04445194 and NCT04466085.Findings Between June 22 and September 15, 2020, 50 participants were enrolled to the phase 1 study (mean age 32.6 years) and 900 participants were enrolled to phase 2 study (mean age 43.5 years), to receive vaccine or placebo with a two-dose or three-dose schedule. For both trials, local and systemic adverse reactions were absent or mild in most participants. There were no serious adverse events related to vaccine in either trial. After three doses, neutralizing antibodies were detected in all participants receiving either 25 μg or 50 μg dose of vaccine in phase 1 study, and in 97% (the 25 μg group) and 93% (the 50 μg group) of participants, respectively, in phase 2 study. The SARS-CoV-2-neutralizing geometric mean titres (GMTs) were 94.5 for the 25 μg group and 117.8 for the 50 μg group in phase 1, and 102.5 for the 25 μg group and 69.1 for the 50 μg group in phase 2, exceeding the level of a panel of COVID-19 convalescent samples (GMT, 51). Vaccine induced balanced TH1 and TH2 responses. The 50 μg group did not show enhanced immunogenicity compared with the 25 μg group.Interpretation The protein subunit vaccine ZF2001 is well-tolerated and immunogenic. The safety and immunogenicity data from phase 1 and 2 trials for ZF2001 support the use of 25 μg vaccine dose with three-dose schedule to an ongoing phase 3 large-scale evaluation for safety and efficacy.Funding National Program on Key Research Project of China, National Science and Technology Major Projects of Drug Discovery, Strategic Priority Research Program of the Chinese Academy of Sciences, and Anhui Zhifei Longcom Biopharmaceutical.Competing Interest StatementSY, EH, CW, and ZZ are employees of Anhui Zhifei Longcom Biopharmaceutical Co. Ltd. YL (Yan Liu) is an employee of Chongqing Medleader Bio-Pharm Co. Ltd. YL (Yi Luo) is an employee of Beijing Keytech Statistical Technology Co. Ltd. LD, YL, JY and GFG are listed as inventors on pending patent applications for RBD- dimer- based CoV vaccines. The pending patents for RBD- dimers as protein subunit vaccines for SARS- CoV-2 have been licensed to Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, China.Clinical TrialNCT04445194, NCT04466085Funding StatementThis work is funded by National Program on Key Research Project of China (2020YFC0842300), National Science and Technology Major Projects of Drug Discovery (2018ZX09101001), Strategic Priority Research Program of the Chinese Academy of Sciences (XDB29010202) and Anhui Zhifei Longcom Biopharmaceutical.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial protocol was approved by the institutional review board of The Second Affiliated Hospital of Chongqing Medical University, Beijing Chao-Yang Hospital of Capital Medical University, Hunan Provincial Center for Disease Control, Prevention and National Medical Products Administration (NMPA), China and was performed in accordance with the Declaration of Helsinki and Good Clinical Practice.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIndividual participant data will be made available on request, directed to the corresponding author (GFG). After approval of a proposal, data can be shared through a secure online platform.